NZ545318A - Pharmaceutical compositions for healing wounds comprising insulin and PKC alpha inhibitor - Google Patents

Info

Publication number

NZ545318A

NZ545318A NZ545318A NZ54531804A NZ545318A NZ 545318 A NZ545318 A NZ 545318A NZ 545318 A NZ545318 A NZ 545318A NZ 54531804 A NZ54531804 A NZ 54531804A NZ 545318 A NZ545318 A NZ 545318A

Authority

NZ

New Zealand

Prior art keywords

wound

insulin

pkc

skin

cells

Prior art date

2003-07-15

Links

• Espacenet
• Global Dossier
• Discuss

• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 583
• 108090001061 Insulin Proteins 0.000 title claims abstract description 297
• 229940125396 insulin Drugs 0.000 title claims abstract description 290
• 102000004877 Insulin Human genes 0.000 title claims abstract description 289
• 230000035876 healing Effects 0.000 title claims abstract description 77
• 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 64
• 239000003112 inhibitor Substances 0.000 title claims abstract description 55
• 208000027418 Wounds and injury Diseases 0.000 title claims description 289
• 206010052428 Wound Diseases 0.000 title claims description 288
• 102100024924 Protein kinase C alpha type Human genes 0.000 title abstract description 3
• 101710109947 Protein kinase C alpha type Proteins 0.000 title abstract description 3
• 206010072170 Skin wound Diseases 0.000 claims abstract description 96
• 230000001939 inductive effect Effects 0.000 claims abstract description 53
• 230000000699 topical effect Effects 0.000 claims abstract description 39
• 238000002360 preparation method Methods 0.000 claims abstract description 17
• 101150020891 PRKCA gene Proteins 0.000 claims description 113
• 239000000203 mixture Substances 0.000 claims description 42
• 206010012601 diabetes mellitus Diseases 0.000 claims description 24
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
• 241001465754 Metazoa Species 0.000 claims description 11
• 239000006210 lotion Substances 0.000 claims description 11
• 239000002674 ointment Substances 0.000 claims description 11
• 208000025865 Ulcer Diseases 0.000 claims description 10
• 239000000725 suspension Substances 0.000 claims description 10
• 239000006071 cream Substances 0.000 claims description 9
• 231100000397 ulcer Toxicity 0.000 claims description 9
• 206010011985 Decubitus ulcer Diseases 0.000 claims description 6
• 208000004210 Pressure Ulcer Diseases 0.000 claims description 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
• 239000007787 solid Substances 0.000 claims description 6
• 206010056340 Diabetic ulcer Diseases 0.000 claims description 5
• 208000000558 Varicose Ulcer Diseases 0.000 claims description 5
• 239000006185 dispersion Substances 0.000 claims description 5
• 239000000843 powder Substances 0.000 claims description 5
• 239000007921 spray Substances 0.000 claims description 4
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
• 208000011231 Crohn disease Diseases 0.000 claims description 3
• 206010053177 Epidermolysis Diseases 0.000 claims description 3
• 208000034693 Laceration Diseases 0.000 claims description 3
• 206010028116 Mucosal inflammation Diseases 0.000 claims description 3
• 201000010927 Mucositis Diseases 0.000 claims description 3
• 201000004681 Psoriasis Diseases 0.000 claims description 3
• 208000017442 Retinal disease Diseases 0.000 claims description 3
• 206010038923 Retinopathy Diseases 0.000 claims description 3
• 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
• 206010042496 Sunburn Diseases 0.000 claims description 3
• 208000002847 Surgical Wound Diseases 0.000 claims description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
• 206010064996 Ulcerative keratitis Diseases 0.000 claims description 3
• 208000032159 Vaginal inflammation Diseases 0.000 claims description 3
• 230000032683 aging Effects 0.000 claims description 3
• 239000007864 aqueous solution Substances 0.000 claims description 3
• 201000010099 disease Diseases 0.000 claims description 3
• 201000005917 gastric ulcer Diseases 0.000 claims description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
• 208000024693 gingival disease Diseases 0.000 claims description 3
• 208000014617 hemorrhoid Diseases 0.000 claims description 3
• 208000027866 inflammatory disease Diseases 0.000 claims description 3
• 230000002757 inflammatory effect Effects 0.000 claims description 3
• 208000031737 Tissue Adhesions Diseases 0.000 claims 1
• 108090000315 Protein Kinase C Proteins 0.000 description 236
• 102000003923 Protein Kinase C Human genes 0.000 description 233
• 210000004027 cell Anatomy 0.000 description 219
• 210000002510 keratinocyte Anatomy 0.000 description 188
• 108010029485 Protein Isoforms Proteins 0.000 description 115
• 102000001708 Protein Isoforms Human genes 0.000 description 115
• 210000003491 skin Anatomy 0.000 description 115
• 230000014509 gene expression Effects 0.000 description 114
• 238000000034 method Methods 0.000 description 104
• 108010068904 lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine Proteins 0.000 description 97
• VBMOHECZZWVLFJ-GXTUVTBFSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]hexanoyl]amino]propanoyl]amino]hexan Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCCN VBMOHECZZWVLFJ-GXTUVTBFSA-N 0.000 description 96
• 230000000694 effects Effects 0.000 description 95
• 108090000623 proteins and genes Proteins 0.000 description 73
• 230000004913 activation Effects 0.000 description 72
• 230000035755 proliferation Effects 0.000 description 69
• 230000029663 wound healing Effects 0.000 description 67
• 230000004069 differentiation Effects 0.000 description 65
• 241000701161 unidentified adenovirus Species 0.000 description 50
• 239000004480 active ingredient Substances 0.000 description 48
• 238000011282 treatment Methods 0.000 description 47
• 208000015181 infectious disease Diseases 0.000 description 45
• 238000001727 in vivo Methods 0.000 description 44
• 241000699670 Mus sp. Species 0.000 description 40
• 239000003102 growth factor Substances 0.000 description 39
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 37
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 37
• 230000008569 process Effects 0.000 description 37
• 230000002018 overexpression Effects 0.000 description 36
• 102000004169 proteins and genes Human genes 0.000 description 36
• 230000002500 effect on skin Effects 0.000 description 34
• 230000005764 inhibitory process Effects 0.000 description 34
• 239000003795 chemical substances by application Substances 0.000 description 32
• 238000000338 in vitro Methods 0.000 description 32
• 230000002062 proliferating effect Effects 0.000 description 32
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 26
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 26
• 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 25
• 235000018102 proteins Nutrition 0.000 description 25
• 238000002474 experimental method Methods 0.000 description 24
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 23
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 23
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 23
• 108020004459 Small interfering RNA Proteins 0.000 description 23
• 239000013598 vector Substances 0.000 description 23
• 239000010410 layer Substances 0.000 description 22
• 210000004927 skin cell Anatomy 0.000 description 22
• 102000006495 integrins Human genes 0.000 description 20
• 108010044426 integrins Proteins 0.000 description 20
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 19
• 239000003981 vehicle Substances 0.000 description 19
• 101800003838 Epidermal growth factor Proteins 0.000 description 18
• 102400001368 Epidermal growth factor Human genes 0.000 description 18
• 230000015572 biosynthetic process Effects 0.000 description 18
• 229940116977 epidermal growth factor Drugs 0.000 description 18
• 230000000638 stimulation Effects 0.000 description 18
• 241000699666 Mus <mouse, genus> Species 0.000 description 17
• 230000006378 damage Effects 0.000 description 17
• 239000003937 drug carrier Substances 0.000 description 17
• 210000001339 epidermal cell Anatomy 0.000 description 17
• 210000004379 membrane Anatomy 0.000 description 17
• 239000012528 membrane Substances 0.000 description 17
• 150000007523 nucleic acids Chemical class 0.000 description 17
• 239000004055 small Interfering RNA Substances 0.000 description 17
• 210000001519 tissue Anatomy 0.000 description 17
• 230000009466 transformation Effects 0.000 description 17
• 230000004663 cell proliferation Effects 0.000 description 16
• 229940088597 hormone Drugs 0.000 description 16
• 239000005556 hormone Substances 0.000 description 16
• 230000006698 induction Effects 0.000 description 16
• 210000002660 insulin-secreting cell Anatomy 0.000 description 16
• 230000001404 mediated effect Effects 0.000 description 16
• 102000039446 nucleic acids Human genes 0.000 description 16
• 108020004707 nucleic acids Proteins 0.000 description 16
• 229940104230 thymidine Drugs 0.000 description 16
• 230000001965 increasing effect Effects 0.000 description 15
• 102000004889 Interleukin-6 Human genes 0.000 description 14
• 108090001005 Interleukin-6 Proteins 0.000 description 14
• 238000003556 assay Methods 0.000 description 14
• 238000010348 incorporation Methods 0.000 description 14
• 230000002401 inhibitory effect Effects 0.000 description 14
• 229940100601 interleukin-6 Drugs 0.000 description 14
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
• 108010081589 Becaplermin Proteins 0.000 description 13
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 13
• 108091000080 Phosphotransferase Proteins 0.000 description 13
• 239000012190 activator Substances 0.000 description 13
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 13
• 239000003814 drug Substances 0.000 description 13
• 210000002615 epidermis Anatomy 0.000 description 13
• 239000000463 material Substances 0.000 description 13
• 102000020233 phosphotransferase Human genes 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• 206010061218 Inflammation Diseases 0.000 description 12
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
• -1 e.g. Proteins 0.000 description 12
• 239000000499 gel Substances 0.000 description 12
• 230000004054 inflammatory process Effects 0.000 description 12
• 239000007788 liquid Substances 0.000 description 12
• 230000037361 pathway Effects 0.000 description 12
• 102000053642 Catalytic RNA Human genes 0.000 description 11
• 102000003706 Complement factor D Human genes 0.000 description 11
• 108090000059 Complement factor D Proteins 0.000 description 11
• 230000033228 biological regulation Effects 0.000 description 11
• 210000002950 fibroblast Anatomy 0.000 description 11
• 238000001415 gene therapy Methods 0.000 description 11
• 108020004999 messenger RNA Proteins 0.000 description 11
• 230000001105 regulatory effect Effects 0.000 description 11
• 230000005945 translocation Effects 0.000 description 11
• 239000013603 viral vector Substances 0.000 description 11
• 108090000994 Catalytic RNA Proteins 0.000 description 10
• 108091062157 Cis-regulatory element Proteins 0.000 description 10
• 206010063560 Excessive granulation tissue Diseases 0.000 description 10
• 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 10
• 102000001253 Protein Kinase Human genes 0.000 description 10
• 210000000270 basal cell Anatomy 0.000 description 10
• 230000002301 combined effect Effects 0.000 description 10
• 238000009472 formulation Methods 0.000 description 10
• 210000001126 granulation tissue Anatomy 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• 230000004807 localization Effects 0.000 description 10
• 108060006633 protein kinase Proteins 0.000 description 10
• 108091092562 ribozyme Proteins 0.000 description 10
• 210000001541 thymus gland Anatomy 0.000 description 10
• 230000035897 transcription Effects 0.000 description 10
• 238000013518 transcription Methods 0.000 description 10
• 230000001131 transforming effect Effects 0.000 description 10
• 238000011144 upstream manufacturing Methods 0.000 description 10
• 108010076365 Adiponectin Proteins 0.000 description 9
• 102000011690 Adiponectin Human genes 0.000 description 9
• 108091027757 Deoxyribozyme Proteins 0.000 description 9
• 101710103106 Guanine nucleotide-binding protein subunit beta-2-like 1 Proteins 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 230000000692 anti-sense effect Effects 0.000 description 9
• 238000013459 approach Methods 0.000 description 9
• 230000024245 cell differentiation Effects 0.000 description 9
• 230000001413 cellular effect Effects 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 238000004519 manufacturing process Methods 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 230000003612 virological effect Effects 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• 238000001262 western blot Methods 0.000 description 9
• 102000014777 Adipokines Human genes 0.000 description 8
• 108010078606 Adipokines Proteins 0.000 description 8
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 8
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 108091034117 Oligonucleotide Proteins 0.000 description 8
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
• 108091023040 Transcription factor Proteins 0.000 description 8
• 239000000478 adipokine Substances 0.000 description 8
• 230000003828 downregulation Effects 0.000 description 8
• 239000003883 ointment base Substances 0.000 description 8
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
• 238000010186 staining Methods 0.000 description 8
• 101100286588 Mus musculus Igfl gene Proteins 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 230000033115 angiogenesis Effects 0.000 description 7
• 210000002469 basement membrane Anatomy 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 210000000805 cytoplasm Anatomy 0.000 description 7
• 230000002222 downregulating effect Effects 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 239000012133 immunoprecipitate Substances 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 230000026731 phosphorylation Effects 0.000 description 7
• 238000006366 phosphorylation reaction Methods 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 238000011160 research Methods 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 6
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 6
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
• 239000011575 calcium Substances 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 238000013461 design Methods 0.000 description 6
• 239000000839 emulsion Substances 0.000 description 6
• 239000011521 glass Substances 0.000 description 6
• PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• 230000000877 morphologic effect Effects 0.000 description 6
• 230000004660 morphological change Effects 0.000 description 6
• 239000002773 nucleotide Substances 0.000 description 6
• 239000003921 oil Substances 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 239000002644 phorbol ester Substances 0.000 description 6
• 230000010076 replication Effects 0.000 description 6
• 239000006228 supernatant Substances 0.000 description 6
• 108010044467 Isoenzymes Proteins 0.000 description 5
• 101710183391 Keratin, type I cytoskeletal 14 Proteins 0.000 description 5
• 108010066321 Keratin-14 Proteins 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 239000013504 Triton X-100 Substances 0.000 description 5
• 229920004890 Triton X-100 Polymers 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 230000000996 additive effect Effects 0.000 description 5
• 239000000853 adhesive Substances 0.000 description 5
• 230000001070 adhesive effect Effects 0.000 description 5
• 230000002411 adverse Effects 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 230000008602 contraction Effects 0.000 description 5
• 210000000172 cytosol Anatomy 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 210000004207 dermis Anatomy 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
• 230000009368 gene silencing by RNA Effects 0.000 description 5
• 210000000301 hemidesmosome Anatomy 0.000 description 5
• 238000001114 immunoprecipitation Methods 0.000 description 5
• 108010028309 kalinin Proteins 0.000 description 5
• 230000035800 maturation Effects 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 230000002297 mitogenic effect Effects 0.000 description 5
• 238000010369 molecular cloning Methods 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 238000012552 review Methods 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 230000010388 wound contraction Effects 0.000 description 5
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
• 108020003589 5' Untranslated Regions Proteins 0.000 description 4
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
• 108010039627 Aprotinin Proteins 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 4
• 108010072051 Glatiramer Acetate Proteins 0.000 description 4
• 108060003393 Granulin Proteins 0.000 description 4
• 101000976075 Homo sapiens Insulin Proteins 0.000 description 4
• 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 4
• 108010070514 Keratin-1 Proteins 0.000 description 4
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 101150036732 PRKCQ gene Proteins 0.000 description 4
• 108091030071 RNAI Proteins 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 239000000074 antisense oligonucleotide Substances 0.000 description 4
• 238000012230 antisense oligonucleotides Methods 0.000 description 4
• 229960004405 aprotinin Drugs 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000027455 binding Effects 0.000 description 4
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 4
• 229960005539 bryostatin 1 Drugs 0.000 description 4
• 239000013592 cell lysate Substances 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 210000000981 epithelium Anatomy 0.000 description 4
• 238000010166 immunofluorescence Methods 0.000 description 4
• 238000010185 immunofluorescence analysis Methods 0.000 description 4
• 230000001771 impaired effect Effects 0.000 description 4
• 238000011065 in-situ storage Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 108010052968 leupeptin Proteins 0.000 description 4
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 238000001000 micrograph Methods 0.000 description 4
• 230000005012 migration Effects 0.000 description 4
• 239000007758 minimum essential medium Substances 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 239000006072 paste Substances 0.000 description 4
• 229950000964 pepstatin Drugs 0.000 description 4
• 108010091212 pepstatin Proteins 0.000 description 4
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 4
• 235000019271 petrolatum Nutrition 0.000 description 4
• 150000004633 phorbol derivatives Chemical class 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 239000012049 topical pharmaceutical composition Substances 0.000 description 4
• 238000010361 transduction Methods 0.000 description 4
• 230000026683 transduction Effects 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• 108020005345 3' Untranslated Regions Proteins 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• 239000004821 Contact adhesive Substances 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 102000003746 Insulin Receptor Human genes 0.000 description 3
• 108010001127 Insulin Receptor Proteins 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 102000043276 Oncogene Human genes 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 239000004264 Petrolatum Substances 0.000 description 3
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 3
• 102100035459 Pyruvate dehydrogenase protein X component, mitochondrial Human genes 0.000 description 3
• LHHQTXPEHJNOCX-UHFFFAOYSA-N Rottlerin Natural products CC(=O)c1c(O)c(C)c(O)c(Oc2c(O)c3C=CC(C)(C)Cc3c(C(=O)C=Cc4ccccc4)c2O)c1O LHHQTXPEHJNOCX-UHFFFAOYSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 102000000887 Transcription factor STAT Human genes 0.000 description 3
• 108050007918 Transcription factor STAT Proteins 0.000 description 3
• 108091023045 Untranslated Region Proteins 0.000 description 3
• 108020000999 Viral RNA Proteins 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 150000001413 amino acids Chemical group 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000009172 bursting Effects 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 238000004624 confocal microscopy Methods 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 150000001982 diacylglycerols Chemical class 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 238000003198 gene knock in Methods 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 230000006377 glucose transport Effects 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
• 230000006801 homologous recombination Effects 0.000 description 3
• 238000002744 homologous recombination Methods 0.000 description 3
• 230000002458 infectious effect Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 230000010354 integration Effects 0.000 description 3
• 238000000021 kinase assay Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 230000005937 nuclear translocation Effects 0.000 description 3
• 238000011580 nude mouse model Methods 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 229940066842 petrolatum Drugs 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 230000006798 recombination Effects 0.000 description 3
• 238000005215 recombination Methods 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 229960004586 rosiglitazone Drugs 0.000 description 3
• DEZFNHCVIZBHBI-ZHACJKMWSA-N rottlerin Chemical compound CC(=O)C1=C(O)C(C)=C(O)C(CC=2C(=C(C(=O)\C=C\C=3C=CC=CC=3)C=3OC(C)(C)C=CC=3C=2O)O)=C1O DEZFNHCVIZBHBI-ZHACJKMWSA-N 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 210000001626 skin fibroblast Anatomy 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
• 229960004441 tyrosine Drugs 0.000 description 3
• 235000015112 vegetable and seed oil Nutrition 0.000 description 3
• 239000008158 vegetable oil Substances 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 2
• 206010001258 Adenoviral infections Diseases 0.000 description 2
• 208000010370 Adenoviridae Infections Diseases 0.000 description 2
• 206010060931 Adenovirus infection Diseases 0.000 description 2
• 108090000644 Angiozyme Proteins 0.000 description 2
• 101150111062 C gene Proteins 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 108050006400 Cyclin Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 101710187001 DNA terminal protein Proteins 0.000 description 2
• 208000008960 Diabetic foot Diseases 0.000 description 2
• 102100030013 Endoribonuclease Human genes 0.000 description 2
• 101710199605 Endoribonuclease Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 2
• 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 description 2
• 102000013266 Human Regular Insulin Human genes 0.000 description 2
• 108010090613 Human Regular Insulin Proteins 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
• 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 2
• 102000011782 Keratins Human genes 0.000 description 2
• 108010076876 Keratins Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• 239000004166 Lanolin Substances 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 2
• 101150111723 PDX1 gene Proteins 0.000 description 2
• 102000042846 PKC family Human genes 0.000 description 2
• 108091082203 PKC family Proteins 0.000 description 2
• 101150010978 PRKCE gene Proteins 0.000 description 2
• 101150001670 PRKCG gene Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010039230 Protein Kinase C-delta Proteins 0.000 description 2
• 102100024923 Protein kinase C beta type Human genes 0.000 description 2
• 102100037340 Protein kinase C delta type Human genes 0.000 description 2
• 102100037314 Protein kinase C gamma type Human genes 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 244000166550 Strophanthus gratus Species 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 108010046075 Thymosin Proteins 0.000 description 2
• 102000007501 Thymosin Human genes 0.000 description 2
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
• 229930003316 Vitamin D Natural products 0.000 description 2
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 208000011589 adenoviridae infectious disease Diseases 0.000 description 2
• 229960003767 alanine Drugs 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 238000000339 bright-field microscopy Methods 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 230000006727 cell loss Effects 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 230000010307 cell transformation Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229960000541 cetyl alcohol Drugs 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 238000011284 combination treatment Methods 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 229940038717 copaxone Drugs 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 239000005547 deoxyribonucleotide Substances 0.000 description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 229960002311 dithranol Drugs 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000003028 elevating effect Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 239000003925 fat Substances 0.000 description 2
• 238000007667 floating Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 229960003776 glatiramer acetate Drugs 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 230000003179 granulation Effects 0.000 description 2
• 238000005469 granulation Methods 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 229940103471 humulin Drugs 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 239000012678 infectious agent Substances 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000003475 lamination Methods 0.000 description 2
• 229940039717 lanolin Drugs 0.000 description 2
• 235000019388 lanolin Nutrition 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
• 229960003343 ouabain Drugs 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 206010033675 panniculitis Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000012660 pharmacological inhibitor Substances 0.000 description 2
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 238000007747 plating Methods 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 229920001296 polysiloxane Polymers 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000002731 protein assay Methods 0.000 description 2
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000023650 regulation of keratinocyte proliferation Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000018040 scab formation Effects 0.000 description 2
• 230000036573 scar formation Effects 0.000 description 2
• 210000004739 secretory vesicle Anatomy 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 230000037380 skin damage Effects 0.000 description 2
• 239000002002 slurry Substances 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 210000004304 subcutaneous tissue Anatomy 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 229960005356 urokinase Drugs 0.000 description 2
• LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 2
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
• 235000019166 vitamin D Nutrition 0.000 description 2
• 239000011710 vitamin D Substances 0.000 description 2
• 150000003710 vitamin D derivatives Chemical class 0.000 description 2
• 229940046008 vitamin d Drugs 0.000 description 2
• 230000037303 wrinkles Effects 0.000 description 2
• QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
• YIRMFCGQZJVDNO-FFXVZKRQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamidopropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]propanoyl]amino]-6-aminohexanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]-6-aminohexanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O YIRMFCGQZJVDNO-FFXVZKRQSA-N 0.000 description 1
• LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 description 1
• CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
• 101150055869 25 gene Proteins 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• 241000239290 Araneae Species 0.000 description 1
• 240000003291 Armoracia rusticana Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010003422 Circulating Thymic Factor Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 241001559589 Cullen Species 0.000 description 1
• 229920001651 Cyanoacrylate Polymers 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 101100181139 Drosophila melanogaster Pkcdelta gene Proteins 0.000 description 1
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
• 102000016942 Elastin Human genes 0.000 description 1
• 108010014258 Elastin Proteins 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 206010014970 Ephelides Diseases 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 102100028314 Filaggrin Human genes 0.000 description 1
• 101710088660 Filaggrin Proteins 0.000 description 1
• 208000003790 Foot Ulcer Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
• 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 description 1
• 241001135569 Human adenovirus 5 Species 0.000 description 1
• 101150088952 IGF1 gene Proteins 0.000 description 1
• 108700012441 IGF2 Proteins 0.000 description 1
• 206010054923 Inflammation of wound Diseases 0.000 description 1
• 230000010625 Insulin Receptor Interactions Effects 0.000 description 1
• 101710186630 Insulin-1 Proteins 0.000 description 1
• 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 1
• 108010065038 Keratin-10 Proteins 0.000 description 1
• 208000001126 Keratosis Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
• 235000019766 L-Lysine Nutrition 0.000 description 1
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
• 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 102100031784 Loricrin Human genes 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 208000003351 Melanosis Diseases 0.000 description 1
• NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
• 206010054949 Metaplasia Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
• MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
• 241000701168 Murine adenovirus 1 Species 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 206010050502 Neuropathic ulcer Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 241000255969 Pieris brassicae Species 0.000 description 1
• 229920002367 Polyisobutene Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
• 101710201186 Protein kinase C-like 1 Proteins 0.000 description 1
• 102100037925 Prothymosin alpha Human genes 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 239000012083 RIPA buffer Substances 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 241001068263 Replication competent viruses Species 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 108091006300 SLC2A4 Proteins 0.000 description 1
• 102000007078 STAT Transcription Factors Human genes 0.000 description 1
• 108010072819 STAT Transcription Factors Proteins 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• 206010040799 Skin atrophy Diseases 0.000 description 1
• 208000028990 Skin injury Diseases 0.000 description 1
• 206010050637 Skin tightness Diseases 0.000 description 1
• 102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 239000006180 TBST buffer Substances 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108010078233 Thymalfasin Proteins 0.000 description 1
• 101800001530 Thymosin alpha Proteins 0.000 description 1
• UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 1
• 102100034998 Thymosin beta-10 Human genes 0.000 description 1
• 101710091218 Thymosin beta-12 Proteins 0.000 description 1
• 102100035000 Thymosin beta-4 Human genes 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 206010062910 Vascular infections Diseases 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 208000037919 acquired disease Diseases 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 108010084938 adenovirus receptor Proteins 0.000 description 1
• 239000012790 adhesive layer Substances 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• 239000002280 amphoteric surfactant Substances 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 229940031955 anhydrous lanolin Drugs 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003527 anti-angiogenesis Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000001139 anti-pruritic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003908 antipruritic agent Substances 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 229960003093 antiseptics and disinfectants Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 108700041737 bcl-2 Genes Proteins 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 210000001736 capillary Anatomy 0.000 description 1
• AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
• 229960004484 carbachol Drugs 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 238000005266 casting Methods 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 239000003093 cationic surfactant Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000009028 cell transition Effects 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 230000009668 clonal growth Effects 0.000 description 1
• 239000011280 coal tar Substances 0.000 description 1
• 230000036569 collagen breakdown Effects 0.000 description 1
• 239000000512 collagen gel Substances 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 238000010226 confocal imaging Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 229940009976 deoxycholate Drugs 0.000 description 1
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
• 229950006137 dexfosfoserine Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229920002549 elastin Polymers 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 231100001129 embryonic lethality Toxicity 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000003890 endocrine cell Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
• 229960002199 etretinate Drugs 0.000 description 1
• 238000011124 ex vivo culture Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 230000027948 extracellular matrix binding Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 230000008442 fetal wound healing Effects 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 239000003349 gelling agent Substances 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 238000010363 gene targeting Methods 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 230000002070 germicidal effect Effects 0.000 description 1
• 230000004190 glucose uptake Effects 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 230000037313 granulation tissue formation Effects 0.000 description 1
• 210000000527 greater trochanter Anatomy 0.000 description 1
• 239000005090 green fluorescent protein Substances 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 108010037536 heparanase Proteins 0.000 description 1
• 230000036732 histological change Effects 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 230000009215 host defense mechanism Effects 0.000 description 1
• 102000055848 human LDHA Human genes 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 210000001822 immobilized cell Anatomy 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 239000008633 juniper tar Substances 0.000 description 1
• 230000029774 keratinocyte migration Effects 0.000 description 1
• 239000003410 keratolytic agent Substances 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 108010079309 loricrin Proteins 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 229960003646 lysine Drugs 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000015689 metaplastic ossification Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229960004469 methoxsalen Drugs 0.000 description 1
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000008747 mitogenic response Effects 0.000 description 1
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 108700021654 myb Genes Proteins 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• 230000017095 negative regulation of cell growth Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000037311 normal skin Effects 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 230000009965 odorless effect Effects 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 239000003605 opacifier Substances 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 238000006213 oxygenation reaction Methods 0.000 description 1
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 108700041181 parathymosin alpha Proteins 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000003209 petroleum derivative Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
• 108010012347 phorbol ester receptor Proteins 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 239000003504 photosensitizing agent Substances 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920002643 polyglutamic acid Polymers 0.000 description 1
• 230000000379 polymerizing effect Effects 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000012514 protein characterization Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 108010014750 prothymosin alpha Proteins 0.000 description 1
• 238000007388 punch biopsy Methods 0.000 description 1
• 238000011536 re-plating Methods 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 108010052833 ribonuclease HI Proteins 0.000 description 1
• 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
• 238000007665 sagging Methods 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 238000007790 scraping Methods 0.000 description 1
• 239000000565 sealant Substances 0.000 description 1
• 210000001732 sebaceous gland Anatomy 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 238000007390 skin biopsy Methods 0.000 description 1
• 230000037393 skin firmness Effects 0.000 description 1
• 230000008470 skin growth Effects 0.000 description 1
• 230000036559 skin health Effects 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 238000002791 soaking Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 229960004274 stearic acid Drugs 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000013517 stratification Methods 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 210000000106 sweat gland Anatomy 0.000 description 1
• 239000011269 tar Substances 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
• 229960004231 thymalfasin Drugs 0.000 description 1
• 230000002992 thymic effect Effects 0.000 description 1
• LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
• 108010044465 thymosin beta(10) Proteins 0.000 description 1
• 108010070478 thymosin beta(14) Proteins 0.000 description 1
• 108010079996 thymosin beta(4) Proteins 0.000 description 1
• 108010079161 thymosin beta(9) Proteins 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 230000008364 tissue synthesis Effects 0.000 description 1
• 108091006106 transcriptional activators Proteins 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000011426 transformation method Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 230000009750 upstream signaling Effects 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000012130 whole-cell lysate Substances 0.000 description 1